AMPK signaling pathway is rapidly activated by T3 and regulates the cardiomyocyte growth

Molecular and Cellular Endocrinology

Volumn 376, Issue 1-2, 2013, Pages 43-50

  Takano, Ana Paula Cremasco ^a   Diniz, Gabriela Placoná ^a   Barreto Chaves, Maria Luiza Morais ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

AMPK; Cardiomyocyte hypertrophy; Thyroid hormone

Indexed keywords

ADENYLATE KINASE; LEUCINE; LIOTHYRONINE; MESSENGER RNA; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

AMPK; CARDIOMYOCYTE HYPERTROPHY; THYROID HORMONE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANIMALS, NEWBORN; CARDIOMEGALY; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HEART VENTRICLES; MYOCYTES, CARDIAC; PRIMARY CELL CULTURE; RATS; RATS, WISTAR; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRIIODOTHYRONINE;

EID: 84879511652     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.05.024     Document Type: Article

References (59)

1. Barreto-Chaves M.L., Heimann A., Krieger J.E. Stimulatory effect of dexamethasone on angiotensin-converting enzyme in neonatal rat cardiac myocytes. Braz. J. Med. Biol. Res. 2000, 33:661-664.
2. Bassett J.H., Harvey C.B., Williams G.R. Mechanisms of thyroid hormone receptor-specific nuclear and extra nuclear actions. Mol. Cell. Endocrinol. 2003, 213:1-11.
3. Beauloye C., Bertrand L., Horman S., Hue L. AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure. Cardiovasc. Res. 2011, 90:224-233.
4. Beg Z.H., Allmann D.W., Gibson D.M. Modulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity with cAMP and wth protein fractions of rat liver cytosol. Biochem. Biophys. Res. Commun. 1973, 54:1362-1369.
5. Bergh J.J., Lin H.Y., Lansing L., Mohamed S.N., Davis F.B., Mousa S., Davis P.J. Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 2005, 146:2864-2871.
6. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
7. Carling D. The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem. Sci. 2004, 29:18-24.
8. Carling D., Sanders M.J., Woods A. The regulation of AMP-activated protein kinase by upstream kinases. Int. J. Obes. 2008, 4(Suppl. 4):S55-S59.
9. Carlson C.A., Kim K.H. Regulation of hepatic acetyl coenzyme A carboxylase by phosphorylation and dephosphorylation. J. Biol. Chem. 1973, 248:378-380.
10. Carrillo-Sepulveda M.A., Ceravolo G.S., Fortes Z.B., Carvalho M.H., Tostes R.C., Laurindo F.R., Webb R.C., Barreto-Chaves M.L. Thyroid hormone stimulates NO production via activation of the PI3K/Akt pathway in vascular myocytes. Cardiovasc. Res. 2010, 85(3):560-570.
11. Chan A.Y., Dyck J.R. Activation of AMP-activated protein kinase (AMPK) inhibits protein synthesis: a potential strategy to prevent the development of cardiac hypertrophy. Can. J. Physiol. Pharmacol. 2005, 83:24-28.
12. Chan A.Y., Soltys C.L., Young M.E., Proud C.G., Dyck J.R. Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J. Biol. Chem. 2004, 279:32771-32779.
13. Chen B.L., Ma Y.D., Meng R.S., Xiong Z.J., Wang H.N., Zeng J.Y., Liu C., Dong Y.G. Activation of AMPK inhibits cardiomyocyte hypertrophy by modulating of the FOXO1/MuRF1 signaling pathway in vitro. Acta. Pharmacol. Sin. 2010, 31:798-804.
14. Corton J.M., Gillespie J.G., Hardie D. Role of the AMP-activated protein kinase in the cellular stress response. Curr. Biol. 1994, 4:315-324.
15. Davies S.P., Helps N.R., Cohen P.T., Hardie D.G. 5'-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C alpha and native bovine protein phosphatase-2AC. FEBS Lett. 1995, 377:421-425.
16. Davis P.J., Davis F.B. Nongenomic actions of thyroid hormone on the heart. Thyroid 2002, 12:459-466.
17. Davis P.J., Leonard J.L., Davis F.B. Mechanisms of nongenomic actions of thyroid hormone. Front. Neuroendocrinol. 2008, 29:211-218.
18. Dillmann W. Cardiac hypertrophy and thyroid hormone signaling. Heart Fail. Rev. 2010, 15:125-132.
19. Diniz G.P., Carneiro-Ramos M.S., Barreto-Chaves M.L. Angiotensin type 1 receptor mediates thyroid hormone-induced cardiomyocyte hypertrophy through the Akt/GSK-3β/mTOR signaling pathway. Basic Res. Cardiol. 2009, 104:653-667.
20. Diniz G.P., Takano A.P., Bruneto E., Silva F.G., Nunes M.T., Barreto-Chaves M.L. New insight into the mechanism associated with the rapid effect of T3 on AT1R. J. Mol. Endocrinol. 2012, 49:11-20.
21. Dyck J.R., Lopaschuk G.D. AMPK alterations in cardiac physiology and pathology: enemy or ally?. J. Physiol. 2006, 574:95-112.
22. Fu Y.N., Xiao H., Ma X.W., Jiang S.Y., Xu M., Zhang Y.Y. Metformin attenuates pressure overload-induced cardiac hypertrophy via AMPK activation. Acta. Pharmacol. Sin. 2011, 32:879-887.
23. Gerdes A.M., Iervasi G. Thyroid replacement therapy and heart failure. Circulation 2010, 122:385-393.
24. Gundewar S., Calvert J.W., Jha S., Toedt-Pingel I., Ji S.Y., Nunez D., Ramachandran A., Anaya-Cisneros M., Tian R., Lefer D.J. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ. Res. 2009, 104:403-411.
25. Hawley S.A., Boudeau J., Reid J.L., Mustard K.J., Udd L., Makela T.P., Alessi D.R., Hardie D.G. Complexes between the LKB1 tumor suppressor, STRAD α/β and MO25 α/β are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2003, 2:28.1-28.16.
26. Hawley S.A., Pan D.A., Mustard K.J., Ross L., Bain J., Edelman A.M., Frenguelli B.G., Hardie D.G. Calmodulin-dependent protein kinase kinase-β is an alternative upstream kinase for AMP-activated protein kinase. Cell. Metab. 2005, 2:9-19.
27. Heather L.C., Cole M.A., Atherton H.J., Coumans W.A., Evans R.D., Tyler D.J., Glatz J.F.C., Luiken J.J.F.P., Clarke K. Adenosine monophosphate-activated protein kinase activation, substrate transporter translocation, and metabolism in the contracting hyperthyroid rat heart. Endocrinology 2010, 24:422-431.
28. Heidrich F., Schotola H., Popov A.F., Sohns C., Schuenemann J., Friedrich M., Coskun K.O., von Lewinski D., Hinz J., Bauer M., Mokashi S.A., Sossalla S., Schmitto J.D. AMPK - activated protein kinase and its role in energy metabolism of the heart. Curr. Cardiol. Rev. 2010, 6:337-342.
29. Henderson K.K., Danzi S., Paul J.T., Leya G., Klein I., Samarel A.M. Physiological replacement of T3 improves left ventricular function in an animal model of myocardial infarction-induced congestive heart failure. Circ. Heart Fail. 2009, 2:243-252.
30. Hiroi Y., Kim H.H., Ying H., Furuya F., Huang Z., Simoncini T., Noma K., Ueki K., Nguyen N.H., Scanlan T.S., Moskowitz M.A., Cheng S.Y., Liao J.K. Rapid nongenomic actions of thyroid hormone. Proc. Natl. Acad. Sci. USA 2006, 103:14104-14109.
31. Horman S., Beauloye C., Vanoverschelde J.L., Bertrand L. AMP-activated protein kinase in the control of cardiac metabolism and remodeling. Curr. Heart Fail. Rep. 2012, 9:164-173.
32. Hu L.W., Liberti E.A., Barreto-Chaves M.L. Myocardial ultrastructure in cardiac hypertrophy induced by thyroid hormone - an acute study in rats. Virchows Arch. 2005, 46:265-269.
33. Hurley R.L., Barré L.K., Wood S.D., Anderson K.A., Kemp B.E., Means A.R., Witters L.A. Regulation of AMP-activated protein kinase by multisite phosphorylation in response to agents that elevate cellular cAMP. J. Biol. Chem. 2006, 281:36662-36672.
34. Jiang S.Y., Xu M., Ma X.W., Xiao H., Zhang Y.Y. Distinct AMPK phosphorylation site characterizes cardiac hypertrophy induced by L-thyroxine and angiotensin II. Clin. Exp. Pharmacol. Physiol. 2010, 37:919-925.
35. Kim M., Tian R. Targeting AMPK for cardiac protection: opportunities and challenges. J. Mol. Cell. Cardiol. 2011, 51:548-553.
36. Kim J., Wende A.R., Sena S., Theobald H.A., Soto J., Sloan C., Wayment B.E., Litwin S.E., Holzenberger M., LeRoith D., Abel E.D. Insulin-like growth factor I receptor signaling is required for exercise-induced cardiac hypertrophy. Mol. Endocrinol. 2008, 22:2531-2543.
37. Kim A.S., Miller E.J., Wright T.M., Li J., Qi D., Atsina K., Zaha V., Sakamoto K., Young L.H. A small molecule AMPK activator protects the heart against ischemia-reperfusion injury. J. Mol. Cell. Cardiol. 2011, 51:24-32.
38. Klein I.E., Ojamaa K. Thyroid hormone and the cardiovascular system. N. Engl. J. Med. 2001, 344:501-509.
39. Meng R.S., Pei Z.H., Yin R., Zhang C.X., Chen B.L., Zhang Y., Liu D., Xu A.L., Dong Y.G. Adenosine monophosphate-activated protein kinase inhibits cardiac hypertrophy through reactivating peroxisome proliferator-activated receptor-α signaling pathway. Eur. J. Pharmacol. 2009, 620:63-70.
40. Musi N., Hirshman M.F., Arad M., Xing Y., Fujii N., Pomerleau J., Ahmad F., Berul C.I., Seidman J.G., Tian R., Goodyear L.J. Functional role of AMP-activated protein kinase in the heart during exercise. FEBS Lett. 2005, 579:2045-2050.
41. Nixon B.R., Thawornkaiwong A., Jin J., Brundage E.A., Little S.C., Davis J.P., Solaro R.J., Biesiadecki B.J. AMP-activated protein kinase phosphorylates cardiac troponin I at Ser-150 to increase myofilament calcium sensitivity and blunt PKA-dependent function. J. Biol. Chem. 2012, 287:19136-19147.
42. Ojamaa K. Signaling mechanisms in thyroid hormone-induced cardiac hypertrophy. Vasc. Pharmacol. 2010, 52:113-119.
43. Oliveira S.M., Zhang Y.H., Solis R.S., Isackson H., Bellahcene M., Yavari A., Pinter K., Davies J.K., Ge Y., Ashrafian H., Walker J.W., Carling D., Watkins H., Casadei B., Redwood C. AMP-activated protein kinase phosphorylates cardiac troponin I and alters contractility of murine ventricular myocytes. Circ. Res. 2012, 110:1192-1201.
44. Pang T., Rajapurohitam V., Cook M.A., Karmazyn M. Differential AMPK phosphorylation sites associated with phenylephrine vs antihypertrophic effects of adenosine agonists in neonatal rat ventricular myocytes. Am. J. Physiol. Heart Circ. Physiol. 2010, 298:H1382-H1390.
45. Pantos C., Mourouzis I., Markakis K., Dimopoulos A., Xinaris C., Kokkinos A.D., Panagiotou M., Cokkinos D.V. Thyroid hormone attenuates cardiac remodeling and improves hemodynamics early after acute myocardial infarction in rats. Eur. J. Cardiothorac. Surg. 2007, 32:333-339.
46. Pantos C., Mourouzis I., Xinaris C., Papadopoulou-Daifoti Z., Cokkinos D. Thyroid hormone and "cardiac metamorphosis": potential therapeutic implications. Pharmacol. Ther. 2008, 118:277-294.
47. Pantos C., Mourouzis I., Tsagoulis N., Markakis K., Galanopoulos G., Roukounakis N., Perimenis P., Liappas A., Cokkinos D.V. Thyroid hormone and recovery of cardiac function in patients with acute myocardial infarction: a strong association?. J. Physiol. Pharmacol. 2009, 60:49-56.
48. Ribeiro R.C., Apriletti J.W., West B.L., Wagner R.L., Fletterick R.J., Schaufele F., Baxter J.D. The molecular biology of thyroid hormone action. Ann. N.Y. Acad. Sci. 1995, 30:366-389.
49. Soltys C.L., Kovacic S., Dyck J.R. Activation of cardiac AMP-activated protein kinase by LKB1 expression or chemical hypoxia is blunted by increased Akt activity. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:H2472-H2479.
50. Stein S.C., Woods A., Jones N.A., Davison M.D., Carling D. The regulation of AMP-activated protein kinase by phosphorylation. Biochem. J. 2000, 345:437-443.
51. Stuck B.J., Lenski M., Böhm M., Laufs U. Metabolic switch and hypertrophy of cardiomyocytes following treatment with angiotensin II are prevented by AMP-activated protein kinase. J. Biol. Chem. 2008, 283:32562-32569.
52. Sugden P.H., Clerk A. Cellular mechanisms of cardiac hypertrophy. J. Mol. Med. 1998, 76:725-746.
53. Tavares F.M., Silva I.B., Gomes D.A., Barreto-Chaves M.L. Angiotensin II type 2 receptor (AT2R) is associated with increased tolerance of the hyperthyroid heart to ischemia-reperfusion. Cardiovasc. Drugs Ther. 2013, (in press).
54. Verhoeven A.J., Woods A., Brennan C.H., Hawley S.A., Hardie D.G., Scott J., Beri R.K., Carling D. The AMP-activated protein kinase gene is highly expressed in rat skeletal muscle. Alternative splicing and tissue distribution of the mRNA. Eur. J. Biochem. 1995, 228:236-243.
55. Wang M.Y., Unger R.H. Role of PP2C in cardiac lipid accumulation in obese rodents and its prevention by troglitazone. Am. J. Physiol. Endocrinol. Metab. 2005, 288:E216-E221.
56. Wong A.K., Howie J., Petrie J.R., Lang C.C. AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease. Clin. Sci. (London) 2009, 116:607-620.
57. Woods A., Johnstone S.R., Dickerson K., Leiper F.C., Fryer L.G., Neumann D., Schlattner U., Wallimann T., Carlson M., Carling D. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr. Biol. 2003, 13:2004-2008.
58. 2+/calmodulin-dependent protein kinase kinase-β acts upstream of AMP-activated protein kinase in mammalian cells. Cell. Metab. 2005, 2:21-33.
59. Zarrinpashneh E., Carjaval K., Beauloye C., Ginion A., Mateo P., Pouleur A.C., Horman S., Vaulont S., Hoerter J., Viollet B., Hue L., Vanoverschelde J.L., Bertrand L. Role of the alpha2-isoform of AMP-activated protein kinase in the metabolic response of the heart to no-flow ischemia. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H2875-H2883.